Genetic testing for cancer in diverse ethnic groups
GEMINI - Cancer Genetic Testing in Ethnic Populations
This study is testing how genetic testing can help cancer patients from different ethnic backgrounds understand their risks and improve their personalized care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 2 sites (Scottsdale, Arizona and 1 other locations) |
| Trial ID | NCT04475640 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the prevalence of genetic mutations in cancer patients from various ethnic backgrounds at Mayo Clinic Arizona and Mayo Clinic Florida. It aims to integrate cancer genetic testing into standard oncology care by collecting blood or saliva samples for analysis. The study will assess the impact of genetic testing on cancer risk stratification and individualized screening, comparing results from multi-gene panel testing to traditional guidelines. By focusing on diverse populations, the trial seeks to enhance understanding of genetic risks associated with different ethnicities.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with solid tumor cancers who self-identify as part of various ethnic populations and are seeking treatment at Mayo Clinic.
Not a fit: Patients who have undergone extensive germline genetic testing within the last 24 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cancer risk assessment and personalized screening strategies for patients from diverse ethnic backgrounds.
How similar studies have performed: Other studies have shown success in integrating genetic testing into cancer care, particularly in diverse populations, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients at least 18 years of age * Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management/treatment; and patients receive genetic testing as described above * Self-identified as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent), Asian and other European populations * Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s) * Individuals have agreed to participate and signed the study informed consent form Exclusion Criteria: * Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent * Past or current history of hematological cancer (including leukemias, multiple myeloma) * All bone marrow transplants
Where this trial is running
Scottsdale, Arizona and 1 other locations
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States (Recruiting)
- Mayo Clinic in Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Jewel Samadder, M.D. — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.